Researchers use cryo-EM and optical tweezers to investigate how an antiviral interacts with the herpes simplex virus.
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose ...
(RTTNews) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase ...
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – “At Gilead, we develop novel antiviral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results